{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T09:59:09Z","timestamp":1777111149716,"version":"3.51.4"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>To describe the pharmacokinetics of flucytosine in a critically ill patient undergoing continuous venovenous hemodiafiltration (CVVHDF) treated for cryptococcal meningitis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>A 20-year-old female weighing 93.4 kg with a body mass index of 34.3 kg\/m2 with a past medical history of systemic lupus erythematous with diffuse proliferative lupus nephritis (class IV) was admitted to the hospital after several months of worsening dyspnea, fatigue, myalgia, vomiting, and diarrhea. The patient developed worsening renal function and volume overload requiring CVVHDF on hospital day 7. She was diagnosed with cryptococcal meningitis on hospital day 8, and flucytosine 2,500 mg enterally every 12 hours and liposomal amphotericin B 500 mg intravenously every 24 hours were initiated. Flucytosine serum concentrations were collected on day 4 of therapy, and pharmacokinetics were performed on 2 sequential levels. Pharmacokinetic calculations displayed an elimination rate constant of 0.0338 h-1, a volume of distribution between 0.42 and 0.43 L\/kg, a half-life of 20.5 hours, and a total drug clearance between 1.32 and 1.36 L\/h while on CVVHDF. The nonsequential levels displayed good correlation, and no further monitoring or dosage adjustment was required. The patient completed therapy, with clinical resolution of her infection, and no toxicities due to flucytosine were noted.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Flucytosine dosed at 25 mg\/kg of actual body weight every 12 hours during CVVHDF conferred therapeutic levels with no appreciable toxicities. Because of its narrow therapeutic index and risk of toxicity, additional pharmacokinetic studies are needed to determine optimal drug dosing of this medication in patients requiring renal replacement therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxaa034","type":"journal-article","created":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T09:08:13Z","timestamp":1585732093000},"page":"609-613","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacokinetics of flucytosine in a critically ill patient on continuous venovenous hemodiafiltration"],"prefix":"10.1093","volume":"77","author":[{"given":"Rebecca A","family":"Greene","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Rhode Island Hospital, Providence, RI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen K","family":"Adams","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Rhode Island Hospital, Providence, RI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph D","family":"Rogers","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Warren Alpert Medical School of Brown University, Providence, RI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Berard-Collins","sequence":"first","affiliation":[{"name":"Lifespan Corporation-Rhode Island Hospital, The Miriam Hospital, Bradley Hospital, Providence, RI, and Lifespan Pharmacy, LLC, Providence, RI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P","family":"Lorenzo","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Rhode Island Hospital, Providence, RI"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,4,1]]},"reference":[{"key":"2020040105051865100_CIT0001","first-page":"78","author":"HS Panel of Opportunistic Infections in HIV-Infected Adults and Adolescents","year":"2016"},{"issue":"3","key":"2020040105051865100_CIT0002","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/649858","article-title":"Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America","volume":"50","author":"Perfect","year":"2010","journal-title":"Clin Infect Dis."},{"issue":"5","key":"2020040105051865100_CIT0003","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology","volume":"69","author":"Ashbee","year":"2014","journal-title":"J Antimicrob Chemother."},{"issue":"2","key":"2020040105051865100_CIT0004","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/0002-9343(87)90691-7","article-title":"Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis","volume":"83","author":"Stamm","year":"1987","journal-title":"Am J Med."},{"issue":"4","key":"2020040105051865100_CIT0005","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/jac\/dkl550","article-title":"Flucytosine therapeutic monitoring: 15 years experience from the UK","volume":"59","author":"Pasqualotto","year":"2007","journal-title":"J Antimicrob Chemother."},{"key":"2020040105051865100_CIT0006"},{"key":"2020040105051865100_CIT0007","first-page":"656","volume-title":"Antibiotic Essentials.","author":"Cunha","year":"2017","edition":"15th ed"},{"key":"2020040105051865100_CIT0008","first-page":"629","volume-title":"John Hopkins Diagnosis and Treatment of Infectious Diseases.","author":"Bartlett","year":"2011","edition":"3rd ed"},{"key":"2020040105051865100_CIT0009","first-page":"130","volume-title":"The Sanford Guide to Antimicrobial Therapy.","author":"Gilbert","year":"2018","edition":"48th ed"},{"key":"2020040105051865100_CIT0010","first-page":"927496","article-title":"Flucytosine pharmacokinetics in a critically ill patient receiving continuous renal replacement therapy","volume":"2015","author":"Kunka","year":"2015","journal-title":"Case Rep Crit Care."},{"issue":"4","key":"2020040105051865100_CIT0011","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000168858","article-title":"Elimination of flucytosine by continuous hemofiltration","volume":"15","author":"Lau","year":"1995","journal-title":"Am J Nephrol."},{"issue":"7","key":"2020040105051865100_CIT0012","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00134-002-1340-4","article-title":"Flucytosine dose requirements in a patient receiving continuous veno-venous haemofiltration","volume":"28","author":"Thomson","year":"2002","journal-title":"Intensive Care Med."},{"issue":"5","key":"2020040105051865100_CIT0013","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1592\/phco.29.5.562","article-title":"Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis","volume":"29","author":"Heintz","year":"2009","journal-title":"Pharmacotherapy."},{"issue":"26","key":"2020040105051865100_CIT0014","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1056\/NEJMct1206045","article-title":"Continuous renal-replacement therapy for acute kidney injury","volume":"367","author":"Tolwani","year":"2012","journal-title":"N Engl J Med."},{"issue":"2","key":"2020040105051865100_CIT0015","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/jac\/46.2.171","article-title":"Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions","volume":"46","author":"Vermes","year":"2000","journal-title":"J Antimicrob Chemother."},{"issue":"6","key":"2020040105051865100_CIT0016","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1097\/00007691-200012000-00006","article-title":"Population pharmacokinetics of flucytosine: comparison and validation of three models using STS, NPEM, and NONMEM","volume":"22","author":"Vermes","year":"2000","journal-title":"Ther Drug Monit."},{"key":"2020040105051865100_CIT0017","first-page":"19","volume-title":"Concepts in Clinical Pharmacokinetics.","author":"Dipiro","year":"2010","edition":"5th ed"},{"issue":"2","key":"2020040105051865100_CIT0018","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/bmc.38","article-title":"Simultaneous determination of flucytosine and fluorouracil in human plasma by high-performance liquid chromatography","volume":"15","author":"Tora\u00f1o","year":"2001","journal-title":"Biomed Chromatogr."},{"issue":"8","key":"2020040105051865100_CIT0019","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1128\/AAC.33.8.1403","article-title":"Performance characteristics of two bioassays and high-performance liquid chromatography for determination of flucytosine in serum","volume":"33","author":"St-Germain","year":"1989","journal-title":"Antimicrob Agents Chemother."},{"issue":"5","key":"2020040105051865100_CIT0020","doi-asserted-by":"crossref","first-page":"a019653","DOI":"10.1101\/cshperspect.a019653","article-title":"Antifungal pharmacokinetics and pharmacodynamics","volume":"5","author":"Lepak","year":"2014","journal-title":"Cold Spring Harb Perspect Med."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/77\/8\/609\/32985580\/zxaa034.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/77\/8\/609\/32985580\/zxaa034.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T09:08:37Z","timestamp":1585732117000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/77\/8\/609\/5814264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,1]]},"references-count":20,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,4,1]]},"published-print":{"date-parts":[[2020,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxaa034","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,4,15]]},"published":{"date-parts":[[2020,4,1]]}}}